logo

News

Press Releases

July 26, 2017
Navigen Presents Promising Pre-Clinical Data on CPT31 at the 9th International AIDS Society Conference on HIV Science
April 25, 2017
Navigen Announces $1.7MM Phase II NIH SBIR Award to Support the Development of ARF6 Inhibitors for Treatment of Acute Lung Injury
October 20, 2016
Dr. Michael Kay Presents Recent Data on Navigen's HIV Entry Inhibitor, CPT31, at the 2016 HIVR4P meeting
August 24, 2016
Navigen Awarded $500,000 Grant to Support Depot Formulation of its HIV Drug Candidate
August 11, 2016
Navigen Announces $3MM Phase II NIH SBIR Award to Support the Development of its Anti-RSV Compound to Prevent and Treat RSV Infections in Children and Adults